|
Police seek 64-year-old man in need of dialysis last seen in Northridge - LA Daily News |
 |
 |
|
Los Angeles police are seeking the public’s help in locating a missing 64-year-old man in need of dialysis last seen in Northridge on Friday morning, authorities said.
John Winfield, who suffers from chronic kidney disease, was last seen about 10:30 a.m. in the 10200 block of Balboa Boulevard, according to a statement by police released Sunday.
He is described as a black male with brown eyes who stands at 5-feet-4-inches and weights about 175 pounds. He was last seen wearing a flat brim hat, white T-shirt and black cargo pants and black “army-style” boots. Winfield, who holds a bus pass, may have gone to Hollywood to buy records, officials said.
Anyone who has seen Winfield or has any information about his whereabouts is urged to contact LAPD Devonshire area detectives at 818-832-0633 or during non-business hours or on weekends at 1-877-LAPD-24-7. Those wishing to remain anonymous can call Crime Stoppers at 1-800-222-8477 or text the phone number 274637 with a cell phone. All text messages should begin with the letters LAPD.
<![CDATA[ #AD_text{ font-size: 11px; color: #999999; } ]]>
Advertisement
|
|
Dashing for dialysis chairs - The Telegram (subscription) |
|
|
|
He lived a relatively pain-free life until he got sick in recent years. His kidneys became enlarged and filled with cysts.
“I turned 50 a couple of years ago, and four or five weeks later I started dialysis. So the good news is they were right. And the bad news is they were right,” he told The Telegram Saturday at the first annual Dialysis Dash in Bowring Park.
Andrews, who’s from Port de Grave and lives in Conception Bay South, said he now spends about 4 ½ hours in a dialysis chair three days a week.
“And boy, I tell you, that was quite a disruption in my life,” he said.
“I used to think, “Poor me. I’m losing Monday, Wednesday, Friday out of my life.’ And then I said, ‘You know what? I’ll make the most out of Monday, Wednesday, Friday, and I’d kick the living crap out of Tuesday, Thursday Saturday and Sunday.’ So that’s what I decided to do,” he said.
He might not run as fast as he used to, but Andrews still ran five kilometres at the fundraiser in 29 minutes. He was one of about 200 people who took part in the Health Care Foundation event, which raised money toward the purchase of new dialysis chairs in Eastern Health facilities.
The old chairs were fairly basic, and made it difficult for Andrews — and hundreds of other dialysis patients in the region — to get comfortable.
“They have no remote mechanism to change your body positions, to raise or lower your back or anything, so if you get uncomfortable, you actually have to ask a nurse to come over, and that’s very difficult for them,” he said, adding he has had a test run in the handful of new chairs that have already been purchased.
“You can actually move your body around however you want, so each time you get uncomfortable, you can change your body position. That’s huge for us. It changes the whole experience for us,” he said.
“I used to think, ‘Poor me. I’m losing Monday, Wednesday, Friday out of my life.’ And then I said, ‘You know what? I’ll make the most out of Monday, Wednesday, Friday, and I’d kick the living crap out of Tuesday, Thursday Saturday and Sunday.’ So that’s what I decided to do.” Vincent Andrews
Andrews, who raised more than $1,100 for the fundraiser, was extremely thankful for the hard work all the participants put in. Because he spends at least 13 hours in one of those chairs every week, it’s personal for him.
“I’m not easily overwhelmed but,” he said, followed by an emotional pause. “Yeah, it meant a lot.”
The tally
At the end of Saturday’s Dialysis Dash, $26,000 had been tallied up and more donations were coming in.
Linda Ivany, regional manager for dialysis for Eastern Health, said each chair costs up to $6,000. Saturday’s haul buys four chairs and change — a good start, but only a fraction of the goal to bring in 55 new chairs.
Ivany said there are about 350 dialysis patients in the region she covers — St. John’s, Carbonear, Burin, Clarenville and Bonavista — and about 450 in the whole province.
While the new chair model provides comfort and ease for patients, it’s also good news for nurses, Ivany said.
“It actually has a foot rest, which — again with the remote — can come up and down. One of the common problems with our patients is they cramp a lot, and prior to this, the patient would actually use the nurse’s leg to push on when they’d get a cramp,” she said, adding foot rests were a “must have” when Eastern Health was looking at chairs.
“If the patient has a critical incident, the chair can go right back flat, whereas before the nurses would have to get in behind it and pull it back and put it down flat.”
Ivany said she was very pleased with the turnout at the inaugural event.
“We’re planning on doing it every year from here on in. We’ve never really had a major fundraiser,” she said.
|
|
|
Zacks Downgrades DaVita HealthCare Partners to Hold (DVA) - WKRB News |
|
|
|
 DaVita HealthCare Partners (NYSE:DVA) was downgraded by Zacks from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Friday, Market Beat.com reports.
According to Zacks, “DaVita’s earnings per share in the second quarter surpassed the Zacks Consensus Estimate. The outperformance came on the back of rise in patient service, capitated and other revenues. DaVita Healthcare’s strength lies in its enhanced service offerings and compelling inorganic growth story. The company’s incessant efforts to upgrade services, its global expansion initiatives and active acquisitions remain impressive and are supported by its strong financial position. The merger of the HealthCare segment with HealthCare Partners also bodes well for long-term growth, although Medicare Advantage (MA) rate cuts may hurt this segment in the future. High debt levels, adverse effects of healthcare reforms, and an increase in MA beneficiaries are other concerns.”
In other news, COO Michael David Staffieri sold 9,050 shares of the company’s stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $84.07, for a total value of $760,833.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Chairman Robert J. Margolis sold 31,400 shares of the company’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $83.39, for a total value of $2,618,446.00. The disclosure for this sale can be found here.
DaVita HealthCare Partners (NYSE:DVA) traded down 0.15% during mid-day trading on Friday, reaching $81.02. The company had a trading volume of 1,107,146 shares. DaVita HealthCare Partners has a 12-month low of $71.43 and a 12-month high of $85.17. The stock has a 50-day moving average of $79.90 and a 200 day moving average of $79.87. The company has a market capitalization of $17.42 billion and a price-to-earnings ratio of 40.96.
DaVita HealthCare Partners (NYSE:DVA) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $0.95 earnings per share (EPS) for the quarter, hitting the Thomson Reuters consensus estimate of $0.95. The firm earned $3.43 billion during the quarter, compared to the consensus estimate of $3.37 billion. DaVita HealthCare Partners’s quarterly revenue was up 8.3% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.95 EPS. On average, analysts expect that DaVita HealthCare Partners will post $3.76 EPS for the current year.
Other analysts also recently issued reports about the company. RBC Capital increased their price target on DaVita HealthCare Partners from $60.00 to $83.00 and gave the company a “sector perform” rating in a research report on Thursday. Vetr downgraded DaVita HealthCare Partners from a “strong-buy” rating to a “buy” rating and set a $88.97 target price for the company. in a research report on Monday, July 13th. Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $80.00 price target on shares of DaVita HealthCare Partners in a report on Tuesday, May 12th. Piper Jaffray lifted their price objective on DaVita HealthCare Partners from $87.00 to $88.00 and gave the company a “buy” rating in a research note on Monday, May 11th. Finally, Susquehanna reaffirmed a “neutral” rating and set a $82.00 price target (up previously from $75.00) on shares of DaVita HealthCare Partners in a research note on Saturday, May 9th. Six analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $85.20.
DaVita HealthCare Partners Inc. consists of two divisions, Kidney Care and HealthCare Partners (NYSE:DVA). Kidney Care is a provider of dialysis services in the United States, treating patients with chronic kidney failure and end stage renal disease (ESRD). Kidney Care division develops innovative clinical care, offers integrated treatment plans, personalized care teams and health-management services. As of December 31, 2014, we provided dialysis and administrative services in the U.S. through a network of 2,179 outpatient dialysis centers in 46 states and the District of Columbia, serving a total of approximately 173,000 patients. HealthCare Partners division is a patient- and physician-focused integrated health care delivery and management company. HealthCare Partners manages and operates medical groups and affiliated physician networks in Arizona, California, Nevada, Florida and New Mexico. As of December 2014, HealthCare Partners had approximately 837,000 members under its care.
To get a free copy of the research report on DaVita HealthCare Partners (DVA), click here. For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DaVita HealthCare Partners Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners and related companies with MarketBeat.com's FREE daily email newsletter.
|
|
Global Dialysis Equipment Market: Industry Analysis and Opportunity Assessment ... - Medgadget.com (blog) |
|
|
Dialysis machines are artificial kidneys that perform kidney functions for patients who have permanent or temporary renal failure.
Dialysis machines use to cleanse the blood and balance its constituents. By the help of this process, the patient blood is circulated through the machine where it is filtered and balance for electrolytes, pH, and fluid concentration before being returned to the patient. One common problem with kidney failure is water retention, therefore it is common for the process to remove several pints of fluid from the blood of the patient.
Chronic kidney disease is defined as a reduced glomerular filtration rate, increased urinary albumin excretion, or both, and is an increasing public health issue. Prevalence is estimated to be 8-16% worldwide. Worldwide, diabetes mellitus is the most common cause of chronic disease, but in some region other causes, such as herbal and environmental toxins are more common.
Dialysis Equipment Market: Drivers and Restraints
Presently, dialysis equipment global market is driven by the aging population, by increasing incidence of end-stage kidney disease, a rising incidence of diabetes and hypertension.
Dialysis equipment global market is drives by the aging population, technological advancement in healthcare industry, increasing incidence of kidney disease, and increase in the number of diabetic and hypertension patients globally, and due to the shortage of kidney donors for transplantation. However, factors such as low awareness about kidney disease and their modalities, reduction in Medicare reimbursement to dialysis centers act as a major barriers for this market.
Browse Full Report@ http://www.futuremarketinsights.com/reports/dialysis-equipment-market
Dialysis Equipment Market: Segmentation
Global dialysis equipment market is segmented into following types
- Hemodialysis Equipment
- Hemodialysis Machines
- Dialyzers (Artificial Kidney)
- Blood Access Device Dialysate
- Peritoneal Dialysis Equipment
- Continuous Cycling Peritoneal Dialysis (CCPD)
- Continuous Ambulatory Peritoneal Dialysis (CAPD)
- Intermittent Peritoneal Dialysis
- Continuous Renal Replacement Therapy Systems
- Dialysis Accessories
Dialysis Equipment Market: Overview
With rapid technological advancement in healthcare industry, increase in aging population, and increasing incidence of kidney disease, the global dialysis equipment market is expected to have healthy growth rate in the forecast period (2015-2025).
Dialysis Equipment Market: Region-Wise Outlook
Depending on geographic regions, the dialysis equipment global market is segmented into seven key regions: North America, South America, Eastern Europe, Western Europe, Asia Pacific, Japan, and Middle East & Africa.
Due to the high population developing regions such as Asia-Pacific (Japan, China, and India) is expected to form new revenue generating pockets for the market players.
Dialysis Equipment Market: Key Players
Some of the key participating major players in dialysis equipment global market are Fresenius Medical Care AG & Co., Gambro AB, Baxter International Inc., Nipro Inc., ALLMED Medical GmbH, Asahi Kasei Corporation and others.
The research report presents a comprehensive assessment of the market and contains thoughtful insights, facts, historical data, and statistically supported and industry-validated market data. It also contains projections using a suitable set of assumptions and methodologies. The research report provides analysis and information according to categories such as market segments, geographies, types, technology and applications.
The report covers exhaustive analysis on:
- Market Segments
- Market Dynamics
- Market Size
- Supply & Demand
- Current Trends/Issues/Challenges
- Competition & Companies involved
- Technology
- Value Chain
Request Report TOC@ http://www.futuremarketinsights.com/toc/rep-gb-711
Regional analysis includes
- North America (U.S., Canada)
- Latin America (Mexico. Brazil)
- Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)
- Eastern Europe (Poland, Russia)
- Asia Pacific (China, India, Australia & New Zealand)
- Japan
- Middle East and Africa (S. Africa, N. Africa)
ABOUT US:
Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services, which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, an aerial view of the competitive framework, and future market trends.
Our research services cover global as well as regional emerging markets such as GCC, ASEAN, and BRICS. Our offerings cover a broad spectrum of industries including Chemicals, Materials, Energy, Technology, Healthcare, and Retail. FMI’s operating model blends cross-disciplinary research experience to deploy in-depth, insightful, and actionable research.
CONTACT:
Future Market Insights
Mr. Sudip saha
616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989,
United States
T: +1-347-918-3531
F: +1-845-579-5705
Email:
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Website: www.futuremarketinsights.com
|
|
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
